Indian government on the verge of blocking Shanghai Fosun’s 1.3 billion-dollar bid to takeover Gland Pharma

Date: 2017-08-01   Author: Pankaj Singh  Category: #news

Indian government on the verge of blocking Shanghai Fosun’s 1.3 billion-dollar bid to takeover Gland Pharma

The Indian Cabinet Committee on Economic Affairs has decided to block the bid offered by Chinese conglomerate Fosun to acquire the Hyderabad-based Indian drug maker Gland Pharma Ltd., as cited by reliable reports. Fosun International Limited had offered an amount of USD 1.3 billion to Gland Pharma, however, the deal has been facing strong objection, while government officials have been citing reasons of the current cross-border stand-off between the two countries. Gland Pharma, as reported, has categorically stated that the organization does not have any inkling of the government’s decision, since the deal has received approval from the Foreign Investment Promotion Board (FIPB) and the Competition Commission of India (CCI) few months before.

This agreement is likely to be Fosun’s largest acquisition in India pharmaceutical market, as the Chinese conglomerate will acquire an 86% stake in Gland Pharma, post the deal. As per statistics, the pharmaceutical market in India is the third largest sector in terms of volume and is expanding enormously subjected to the deployment of favorable Foreign Direct Investment (FDI) policies by the Indian government, in a bid to attract foreign investors. For the record, Gland Pharma is one of the dominant players of injectables market and has made it to the headlines for the development of various advanced technologies. The organization is also reputed to have established the Heparin technology in India and is a global leader in the Glycosaminoglycans range of molecules. On these grounds, experts vouch for the fact that Fosun stands to gain heavily from Gland Pharma Ltd.

Fosun has been waiting for the deal approval from the Cabinet Committee on Economic Affairs of India, however, on the basis of the political tensions between both the nations, it is likely that the deal may be blocked by the Committee. The company has stated that the Chinese authorities have sanctioned the takeover of the Indian injectable drugmaker. The latest news bulletin states that the approval date for this deal has been extended to September 26. Losing the nation’s mammoth pharma company to the traditional rival in the pharmaceutical sector has been posing controversial questions to the Indian regulators. Also, there are chances that this deal may reduce the importance of India’s contribution to the pharma industry over the years ahead.

Gland Pharma has been contributing majorly to the Indian drug making sector, which mainly encompasses the development of syringes, pumps, bags, and vials. These injectables are very difficult to produce as compared to regular drugs. This deal will handover all four factories of Gland Pharma, based in Hyderabad, to Fosun. The senior executive of Gland Pharma is surprisingly not expecting any hurdles blocking the success of this deal. Since no official confirmation has been received regarding the deal opposition any way, it is likely that the agreement may bear fruit sooner or later.



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Cloud Music Streaming Market Growth By Top Companies with Forecast 2025

Author: Sachin Pashte

The Cloud Music Streaming market research report provides a broad perspective of the major development trends, restraints, remuneration forecasts, and growth rate of this business space, alongside COVID-19 impact analysis.

The research l...


Pharmaceutical Cartridges Market 2020 Global Analysis, Trends, Forecast up to 2025

Author: Sachin Pashte

Global Pharmaceutical Cartridges Market research report, added by Market Study Report LLC, is covering all major industry aspects and touches key scenarios like top players, competition, types, applications, regions, recent developments and future...


Intravenous (IV) Iron Drugs Market: Qualitative Analysis of the Leading Players and Competitive Industry Scenario, 2025

Author: Sachin Pashte

Global Intravenous (IV) Iron Drugs Market Report provides complete industry analysis, market outlook, size, growth, opportunities and forecast 2025. This report will assist in analyzing the current and future business trends, sales and revenue for...